Expert Interview

Upfront Transplants in Patients With Mantle Cell Lymphoma

Author and Disclosure Information

 

I want to touch on health literacy and disparities for a moment. I have some younger patients who are Latin or Black with uncontrolled hypertension or diabetes, even at a young age, and do not realize that I can treat their cancer into remission, but if their blood glucose is in the 500 range, they could die from their diabetes. So talking with patients about their overall health is important. Survivorship issues are important, especially if patients are diagnosed at a young age. We have known for a long time that chemotherapy can create cardiac events, arrhythmias, and heart disease. Therefore, I always tell patients with metabolic syndrome to try to exercise and eat healthy. Patients should get an electrocardiogram and see an internist at least once a year to make sure their cholesterol is well controlled. I think now we are being more cognizant that many complications can happen even 10 years after cancer treatment.

Pages

Recommended Reading

Phase 3 trial yields better way to predict MCL outcomes
MDedge Hematology and Oncology
Blame MCL, not transplantation, for late effects?
MDedge Hematology and Oncology
Transplant provides no clear survival benefit in real-world MCL study
MDedge Hematology and Oncology
High cost and demand for old cancer drug sparks crisis
MDedge Hematology and Oncology
ASH 2022: New clinical data challenge long-held assumptions
MDedge Hematology and Oncology
MCL: Ibrutinib could become the ‘new standard’
MDedge Hematology and Oncology
MCL: Event-free survival at 2 years bodes well
MDedge Hematology and Oncology
Recent Developments in Mantle Cell Lymphoma: Reflections From ASH 2022
MDedge Hematology and Oncology
FDA approves pirtobrutinib for r/r mantle cell lymphoma
MDedge Hematology and Oncology
Erythema extent predicts death in cutaneous GVHD
MDedge Hematology and Oncology